ARTICLE | Company News
Amorfix, BioMosaics Inc. deal
May 4, 2009 7:00 AM UTC
The companies will use Amorfix's Epitope Protection technology with BioMosaics' mAbs against glypican 3 (GPC3) to develop a blood-based assay for the early detection of hepatocellular carcinoma (HCC)...